Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:52:13.287Z.
Calculation as of: 2026-10-06T21:52:13.287Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4147f1633fe526555426f89ecb5945f37dfc8ef4561f7e6db8f1148c00751c21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$5.87B
EV/EBIT Ratio
56.94x
TTM Avg
100.68x
3Y Avg
164.20x
5Y Avg
127.24x
Market Cap
$5.95B
EV/EBIT Ratio
60.20x
TTM Avg
129.47x
3Y Avg
397.21x
5Y Avg
199.00x
Market Cap
$5.52B
EV/EBIT Ratio
315.75x
TTM Avg
339.84x
3Y Avg
339.84x
5Y Avg
339.84x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 56.94x | 100.68x | 164.20x | 127.24x |
| GRAIL Inc. (GRAL)vs › | $5.89B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 60.20x | 129.47x | 397.21x | 199.00x |
| RadNet, Inc. (RDNT)vs › | $5.53B | 76.87x | 86.80x | 66.21x | 59.67x |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 315.75x | 339.84x | 339.84x | 339.84x |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 42.69x | 18.27x | 13.52x | 13.52x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
